「yoshida1」の検索結果
69件：21～25件目を表示
もしかして
-
August 20, 2026 General Announcement: Senju Pharmaceutical Co., Ltd. Senju initiated Phase III Clinical Trials in Japan for "SJP-0049" for the treatment of Allergic Conjunctivitis Senju Phar
https://www.senju.co.jp/system/files/content_news/2026-08/ENG_20260820.pdf -
General Announcement: September 6, 2024 Senju Pharmaceutical Co., Ltd. Launch of Distribution of Software for Dry-eye Analysis Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr
https://www.senju.co.jp/system/files/content_news/2024-09/ENG_20240906.pdf -
General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr.
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf -
General Announcement: September 6, 2024 Senju Pharmaceutical Co., Ltd. Launch of Distribution of Software for Dry-eye Analysis Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr
https://www.senju.co.jp/system/files/content_news/2024-09/ENG_20240906_0.pdf -
发表论文 | 研究与开发 | 千寿制药株式会社
cretion in healthy subjects:A randomized, double-blind, placebo-controlled, crossover study Keisuke Yoshida1, Ryuji Takeda2, and Osamu Sakai1. 1 Senju Pharmaceutical, Co., Ltd., 2 Kansai University of...
http://www.senju.co.jp/chinese/rd/thesis/